US investor adds diagnostic company to portfolio:
This article was originally published in Clinica
Syngen Research, a US research company with proprietary diagnostic DNA amplification technologies, is to become part of the growing portfolio of Aethlon Medical. Aethlon, formerly Bishop Equities, is acquiring medical device technologies to commercialise on an international basis. Recently it gained Hemex, which has a blood purification technology device. In conjunction with a dialysis machine, the device, known as Hemopurifier, can remove targeted intoxicants such as iron, lead and aluminium from the blood. Future products in development include Hemopurifiers designed to remove certain viruses, plutonium and drug overdoses. Syngen and Aethlon are based in San Diego, California.
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”